First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers
Status:
Unknown status
Trial end date:
2020-03-30
Target enrollment:
Participant gender:
Summary
First in human study, assessing the safety profile, the pharmacokinetics and preliminary
antitumor activity of GM102, a new compound (a monoclonal antibody), in patients with
previously treated gynecological cancers bearing the AMHRII (anti-mullerian Hormone Receptor
II) receptor. The primary objective of the study is to determine the GM102 recommended dose.